Ambryx is a leader in discovering and developing a new class of drugs that targets cancer metabolism. The innovative platform is based on the concept that certain embryonic proteins can selectively cause cancer cells, which acquired embryonic properties through mutations, to undergo program cell death. Using a combination of phenotypic screening of embryonic proteins and iterative library mapping, Ambryx has identified a unique group of proteins and its active domains that have anti-cancer properties as well as impact on other disease areas. Ambryx is a privately held life sciences company based in Riverside, California.
CEO: Olof Mollstedt
Olof Mollstedt serves as the Chief Executive Officer at Ambryx. Prior to joining Ambryx Olof served as an internal consultant for Nestlé’s Innovation Acceleration Team, working across the globe with strategic product innovations and creating new business opportunities. He was earlier part of the Nestlé High Performing Operations team, working with manufacturing productivity improvements in China and procurement rationalizations in Europe. His area of specialties include manufacturing, R&D methodology, computational physics. He received his B.S. and M.S. degree in Engineering Physics from Chalmers University of Technology in Sweden, performing his thesis work at NASA Ames Research Center in California.
President & Founder: David Tsai, Ph.D.
Dr. Tsai is the Founder and president of Ambryx, with more than 30 years of scientific research experience in the pharmaceutical industry. Before starting Ambryx, he was a Research Scientist at the Roche Institute of Molecular Biology, Cleveland Clinic Foundation, Sphinx Pharmaceuticals and Amgen. His extensive experience inspired the inception of R-ACT© Technology to isolate bioactive proteins. Dr. Tsai received his B.S. degree from Kaohsiung Medical College in Taiwan, M.S. degree from National Taiwan University, and his Ph.D. from Purdue University.
Chief Operations Officer, Helen Chen, Ph.D.
Dr. Helen Chen serves as the Chief Operations Officer at Ambryx. Prior to joining Ambryx, Dr. Chen was a project analyst at Beachhead Consulting, a leading strategic advisement firm to many of the companies specializing in drug discovery tools development. She was also the co-founder and partner of the Technology Evaluation Group, a consulting firm that specializes in the technology assessment of pharmaceutical compounds and medical devices for venture capitalists and biotech start-up companies. She received her Ph.D. in Biomedical Sciences from the University of California, San Diego, and her B.S. degree from Yale University.
Yuan Chuan Lee, Ph.D. Professor, Johns Hopkins University
Area of specialty: Glycobiology
Recipient of The Rosalind Kornfeld Award for Lifetime Achievement in Glycobiology
Joseph Thompson, Ph.D. Senior Consultant, OSI Pharmaceuticals
Senior consultant of Drug Discovery and Development
Area of specialty: Apoptosis.